Overview
US oncology drug developer posted Q4 net loss, narrowing from prior year
Full-year net income turned positive
R&D and G&A expenses fell
Outlook
Black Diamond expects cash position to fund operations into 2H 2028
Result Drivers
COST REDUCTIONS - Co said lower R&D and G&A expenses were due to workforce efficiencies, restructuring, and portfolio focus
Company press release: ID:nGNXbY7cGL
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$15.1 mln
Q4 Basic EPS
-$0.27
Q4 Income From Operations
-$17.61 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $8.50, about 300.9% above its March 13 closing price of $2.12
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
